Jun 16, 2026 08:02AM
Jun 16, 2026 08:00AM
Jun 4, 2026 04:48PM
Jun 2, 2026 08:01AM
Jun 2, 2026 08:00AM
May 26, 2026 06:59AM
May 14, 2026 08:03AM Cingulate reports Q1 2026 results, raises $14.9M in cash
May 14, 2026 08:00AM
Apr 6, 2026 04:34PM
Mar 18, 2026 08:00AM
Feb 17, 2026 08:02AM
Feb 17, 2026 08:00AM
Nov 18, 2025 04:27PM
Nov 13, 2025 08:00AM Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 10, 2025 08:01AM
Nov 10, 2025 08:00AM
Oct 28, 2025 08:01AM
Oct 28, 2025 08:00AM
Oct 23, 2025 04:45PM
Oct 14, 2025 08:04AM
Oct 14, 2025 08:00AM FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date
Sep 17, 2025 08:45AM
Sep 17, 2025 08:45AM
Aug 21, 2025 04:35PM
Aug 19, 2025 08:45AM
Aug 15, 2025 09:02AM
Aug 15, 2025 09:00AM
Aug 6, 2025 08:45AM Cingulate submits FDA application for ADHD drug CTx-1301
Aug 6, 2025 08:45AM
Jul 29, 2025 08:01AM
Jul 29, 2025 08:00AM
Jul 9, 2025 08:03AM
Jul 9, 2025 08:00AM
Jun 18, 2025 08:00AM
May 20, 2025 08:03AM Cingulate Inc (CING): Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
May 20, 2025 08:00AM
May 14, 2025 08:04AM
May 14, 2025 08:00AM
May 8, 2025 04:30PM
Apr 29, 2025 08:00AM
Apr 3, 2025 08:06AM
Apr 3, 2025 08:00AM Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
Mar 26, 2025 05:00PM
Mar 4, 2025 09:02AM
Mar 4, 2025 09:00AM
Jan 30, 2025 06:40AM
Jan 7, 2025 07:30AM
Dec 23, 2024 07:30AM
Nov 7, 2024 07:30AM Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Sep 12, 2024 08:30AM

323,579 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All